CCN3 and hepatocellular carcinoma: To validate this effect, we treated HCC cells with recombinant CCN3 in a dose-dependent manner (0–10 micro g/mL) and confirmed the activation of ERK and NFκB signaling pathways with concomitant upregulation of OPN, TF, and thrombin (Fig. 5A).